Biogen Inc.

LSE:0R1B Voorraadrapport

Marktkapitalisatie: US$25.3b

Biogen Toekomstige groei

Future criteriumcontroles 1/6

Biogen is forecast to grow earnings and revenue by 13.6% and 1.7% per annum respectively. EPS is expected to grow by 14.3% per annum. Return on equity is forecast to be 13.2% in 3 years.

Belangrijke informatie

13.6%

Groei van de winst

14.3%

Groei van de winst per aandeel

Biotechs winstgroei37.3%
Inkomstengroei1.7%
Toekomstig rendement op eigen vermogen13.2%
Dekking van analisten

Good

Laatst bijgewerkt04 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

LSE:0R1B - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20269,7472,3742,5742,92422
12/31/20259,5622,0852,4022,75528
12/31/20249,6361,7792,0822,45228
9/30/20249,6081,6151,7682,127N/A
6/30/20249,6721,1591,5711,784N/A
3/31/20249,6631,1671,2841,645N/A
12/31/20239,8361,1611,2361,547N/A
9/30/20239,9931,4621,0261,360N/A
6/30/20239,9722,6651,1231,428N/A
3/31/202310,1053,1311,4211,678N/A
12/31/202210,1733,0471,1411,384N/A
9/30/202210,3632,8652,1732,398N/A
6/30/202210,6342,0592,3152,542N/A
3/31/202210,8201,4502,7733,033N/A
12/31/202110,9821,5563,3453,640N/A
9/30/202111,1011,5462,1072,435N/A
6/30/202111,6981,9182,4612,810N/A
3/31/202112,6043,0123,1493,532N/A
12/31/202013,4454,0013,6784,230N/A
9/30/202014,2635,0825,8416,557N/A
6/30/202014,4875,9276,3497,071N/A
3/31/202014,4225,8796,2827,086N/A
12/31/201914,3785,8896,4097,079N/A
9/30/201914,2335,3966,3847,014N/A
6/30/201914,0725,2946,3247,055N/A
3/31/201913,8124,6675,3826,190N/A
12/31/201813,4534,4315,3026,188N/A
9/30/201813,2343,1874,8555,811N/A
6/30/201812,8722,968N/A5,703N/A
3/31/201812,5942,964N/A5,773N/A
12/31/201712,2742,539N/A4,551N/A
9/30/201711,8393,486N/A4,615N/A
6/30/201711,7173,293N/A3,978N/A
3/31/201711,5333,480N/A3,807N/A
12/31/201611,4493,703N/A4,587N/A
9/30/201611,4163,885N/A4,046N/A
6/30/201611,2383,818N/A3,950N/A
3/31/201610,9363,695N/A3,999N/A
12/31/201510,7643,547N/A3,919N/A
9/30/201510,5653,599N/A3,609N/A
6/30/201510,2993,490N/A3,627N/A
3/31/201510,1283,277N/A3,570N/A
12/31/20149,7032,935N/A2,942N/A
9/30/20149,0282,509N/A2,878N/A
6/30/20148,3452,139N/A2,636N/A
3/31/20147,6471,916N/A2,271N/A
12/31/20136,9321,862N/A2,345N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: 0R1B's forecast earnings growth (13.6% per year) is above the savings rate (1.9%).

Winst versus markt: 0R1B's earnings (13.6% per year) are forecast to grow slower than the UK market (14.4% per year).

Hoge groeiwinsten: 0R1B's earnings are forecast to grow, but not significantly.

Omzet versus markt: 0R1B's revenue (1.7% per year) is forecast to grow slower than the UK market (3.6% per year).

Hoge groei-inkomsten: 0R1B's revenue (1.7% per year) is forecast to grow slower than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: 0R1B's Return on Equity is forecast to be low in 3 years time (13.2%).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y